About Alector
Alector is a publicly listed company based in San Francisco (United States) founded in 2013. Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. Alector has raised $214.78 million across 6 funding rounds from investors including AbbVie, New Leaf Venture Partners and HHS. The company has 211 employees. Alector offers products and services including AL101/GSK4527226 and Pipeline Therapies. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Alector, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Alector was founded in 2013 and is headquartered in San Francisco, United States. Immuno-modulatory therapies targeting dementia and other neurodegenerative disorders are developed by the company. Antibody drugs engaging neuro-immune targets validated genetically are included in the pipeline. Drug candidates such as AL001 for dementia, AL101 for neurology, AL002 and AL003 for Alzheimers, AL014 for Alzheimers, and AL008 for oncology are advanced. Operations focus on biotechnology within the healthcare sector.
- Headquarters San Francisco, United States
- Employees 211
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website alector.com
- Social LinkedIn X
- Legal Name Alector, Inc.
- Annual Revenue$21.05 M (USD)-79.07as on Dec 31, 2025
- Net Profit-$142.93 M (USD)-20.06as on Dec 31, 2025
- EBITDA-$136.15 M (USD)-1.64as on Dec 31, 2025
- Total Equity Funding$214.78M (USD)
in 6 rounds
- Latest Funding Round$133M (USD), Series E
Jul 2018
- InvestorsAbbVie
& 19 more
- Employee Count211
Products & Services of Alector
Alector offers a comprehensive portfolio of products and services, including AL101/GSK4527226 and Pipeline Therapies.
Drug for early Alzheimer's disease treatment in clinical trials.
Candidates targeting FTD and ALS for disease modification.
Funding Insights of Alector
Alector has successfully raised a total of $214.78M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $133 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $214.78M
- Total Rounds 6
- Last Round Series E — $133M
- Investors Count 20
All 6 funding rounds of Alector with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2018 | $133M | Series E | – | – | |
| Oct 2017 | $20M | Series D | – | AbbVie | – |
| Sep 2016 | $1.45M | Grant | – | – | |
| Jan 2016 | $29.5M | Series D | – | Amgen Business Development, AbbVie | |
| Sep 2015 | $32.28M | Series C | – | – | – |
| Oct 2013 | Series A | – | – |
20 investors in total: 20 institutional.
Investors in Alector
Alector has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, New Leaf Venture Partners and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Seed and early-stage therapeutics companies are invested in by MRLV. | mrlv.com | Cambridge, United States | ||
US focused VC firm | missionbaycapital.com | San Francisco, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States |
Investor details for Alector
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alector
93 people are tracked at Alector (47 in leadership, 15 in board & advisors, 31 in team); the tracked headcount is 211.
| Name | Role | Group |
|---|---|---|
Clare Hunt | Chief People Officer | Leadership |
Bowen Shi | Director, SEC Reporting And Technical Accounting | Leadership |
Jinglin Zhong | Senior Director, Biostatistics | Leadership |
Balasubrahmanyam B. | Vice President, Clinical And Quantitative Pharmacology | Leadership |
Jorge M. | Associate Director, CMC Technical Operations | Leadership |
Jennifer Shi | Senior Director Clinical Development Operations | Leadership |
Alicia Borris | Director Of Accounting Operations | Leadership |
Naveen Bazaj | Head Of Corporate Development | Leadership |
Cameron Hagen | Corporate Law Director | Leadership |
Kristina Cutter | Chief Development Officer (cdo) | Leadership |
Laura Murray | Senior Director, Program Team Leader | Leadership |
Alusha Mamchak | Director Portfolio And Project Management - Research | Leadership |
Catalina Hathaway | Talent Partner | Leadership |
Kevin McCauley | Vice President, Technical Operations & Supply Chain | Leadership |
Janel Boyce-Rustay | Vice President Regulatory Affairs | Leadership |
Clare Hunt (she/her) | Chief People Officer | Leadership |
Dan Monahan | Director, Head Of Talent Acquisition | Leadership |
George Demos | Vice President | Leadership |
Kristina Rolleri (Krissi) | Director Of Facilities | Leadership |
Krystyna Grycz | Director Clinical Operations | Leadership |
73 more people are available in the full profile.
Complete people profiles for Alector
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Alector
Alector is a publicly listed company on the NASDAQ with ticker symbol ALEC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Feb 2019
- Listed onNASDAQ: ALEC
- Listed entityAlector, Inc.
- Exchange sectorHealth technology
- ISINUS0144421072
- Share price$1.87 (-10.1% on the day) · 2026-10-13
- Market capitalisation$208.8M
- EPS (diluted, trailing year)$-1.09
- Volume (last session)2,843,592
Financials of Alector
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $21.1M | -$142.9M | -$136.2M |
| 2024 | $100.6M | -$119.0M | -$133.9M |
| 2023 | $97.1M | -$130.4M | -$142.9M |
| 2022 | $133.6M | -$133.3M | -$129.4M |
| 2021 | $207.1M | -$36.3M | -$29.1M |
Detailed financial statements for Alector
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Alector
4 dated milestones of Alector across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Alector is founded.
- Funding First funding round.
- Funding Latest funding round, Series E, of $133.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Alector
Alector has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Alector
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alector
The website of Alector (alector.com) receives about 6.1K visits a month and ranks #3,370,379 among all websites worldwide, #4,410 in Biotechnology and Pharmaceuticals.
- Monthly visits6.1K
▼ 0.9% vs previous month
- Unique visitors2.6K
per month
- Global rank#3,370,379
among all websites
- Category rank#4,410
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.5
- Average visit29 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Alector. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sagerx.com | 100% | 8.4K | #2,562,704 | View details | |
| lundbeck.com | 92% | 137.6K | #280,857 | View details | |
| mayo.edu | 55% | 1.7M | #32,445 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Alector (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alector
Complete news archive for Alector
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alector
Alector was founded in 2013.
Alector is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Alector is a funded company, having raised a total of $214.78M across 6 funding rounds to date.
Alector has 211 employees.
Annual revenue of Alector is $21.05M as on Dec 31, 2025.
Alector was founded in 2013 and is headquartered in San Francisco, United States. Immuno-modulatory therapies targeting dementia and other neurodegenerative disorders are developed by the company. Antibody drugs engaging neuro-immune targets validated genetically are included in the pipeline. Drug candidates such as AL001 for dementia, AL101 for neurology, AL002 and AL003 for Alzheimers, AL014 for Alzheimers, and AL008 for oncology are advanced. Operations focus on biotechnology within the healthcare sector.
Alector offers AL101/GSK4527226 and Pipeline Therapies.
Yes, Alector is publicly traded on NASDAQ under the ticker symbol ALEC.
Alector has 20 investors. Key investors include AbbVie, New Leaf Venture Partners, HHS, Orbimed, and Perceptive Advisors.
Alector operates through Alector, Inc..